Arrhythmia recurrence
48 of 53 (91%) patients completed 1 year follow up, with an average
follow up length of 11.5 ± 1.9 months. Follow up length was similar
between the two groups. Overall 6 patients (11%) had long term
continuous monitoring with an implantable device (PPM, ICD, or ILR),
equally distributed between groups. The remaining patients underwent 1
or 2-week ambulatory event monitoring at 3, 6, and 12 months
post-procedure (average 2.3 ± 1.1 monitors). 87% of patients were
maintained on an anti-arrhythmic medication (Amiodarone, Dronedarone, or
Flecainide) for one month post-procedure, and 85% of patients were
continued on long term beta-blocker and/or calcium channel blocker
therapy (Table 1). One year arrhythmia-free survival was similar between
the atrial-paced and ventricular-paced patients (78% vs 67%, p = 0.31)
(Figure 3).